Potential Biomarkers in Prostate Cancer
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Clinical Pearls:
- There are a large number of genomic markers being looked at such as specific genetic alterations in circulating tumor cells
- These potential biomarkers are still being researched but are providing prognostic information and genomic information
- Although many biomarkers are being researched, none yet have the potential to displace PSA
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
